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Background: The prevalence of liver steatosis in patients with CF is reported to
be 23−67%. These estimates are from histopathological studies performed following
clinical or biochemical indication of hepatic abnormality. The ability of ultrasound scan
(USS) of liver parenchyma to differentiate features consistent with fatty inﬁltration
(increased reﬂectivity) from ﬁbrosis (heterogeneity) has long been established.
In 1996 we reported a cross sectional survey of liver USS in 85 patients, age
mean(±SD) = 11.14(±4.1) years. Fatty liver was seen in 3 patients and heterogeneous
parenchyma in 28 (33%).
Aim: To review the liver USS ﬁndings in our current paediatric CF clinic.
Methods: Every child over 5 years old has liver USS performed as part of annual
assessment by one of a limited number of experienced sonographers. Fatty liver was
deﬁned as increased reﬂectivity of the liver parenchyma. All assessments performed in
2009 were reviewed.
Results: Liver USS was performed on 90 patients mean age(±SD) = 11.84(±3.44)
years. The results are presented in the table.
Liver USS parenchyma
Normal
(N = 62, 68.9%)
Fatty
(N = 25, 27.8%)
Heterogeneous
(N= 3, 3.3%)
Male 33 (53.2%) 7 (28%) 3 (100%)
Age (y), mean±SD 11.43±3.55 12.63±2.75 13.81±5.12
BMI centile, median (range) 51.2 (0.3–94.7) 47 (15.9–89.6) 21.2 (8−75)
Homozygous DF508 42 (67.7%) 14 (56%) 1 (33.3%)
CFRD 2 (3.2%) 4 (16%) 0
Pancreatic insufﬁciency 61 (98.4%) 24 (96%) 3 (100%)
Conclusion: Compared to 1996 USS diagnosed fatty liver has become more common
with a decrease in ﬁbrosis. CFRD and female sex were more prevalent in the patients
with fatty liver on USS. As the survival of people with CF continues to increase it is
essential to determine the signiﬁcance of this non-alcoholic fatty liver disease
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Background: CF liver disease (CFLD) is common among patients with CF with
an incidence of 10%. It is a major cause of morbidity and mortality. Early
diagnosis of CFLD is difﬁcult and often missed until advanced liver disease and
portal hypertension are present. The aim of this study is to implement the Stuart
Ultrasound Scoring System (SUSS), a new Ultrasound scoring system, in children
with CF, to assess its ability to diagnose CFLD and consider early intervention.
Methods: The SUSS protocol includes evaluation of: liver edge and texture, size
of spleen, portal tracts and hepatic vein waveform. These parameters were scored
either as normal (1) or abnormal (2). In addition, the liver was categorized according
to the general appearance as normal (A), bright or echogenic (B) and granular (C).
A normal score is A5, and any other score is abnormal. Furthermore, portal vein
and hepatic artery and vein diameter were measured. Investigations included AST,
ALT, GGT, albumin and INR.
Results: Ultrasound was performed on 22 patients (aged 2 to 34 years old) with
CF. Two of them have known CFLD. 15 had normal score (A5) and 7 patients
(33%) had abnormal scores ranging from A8 to C10; including the patients with
CFLD but the rest were not thought to have liver disease previously. There was no
correlation between the SUSS score and biochemical liver function.
Summary and Conclusions: This preliminary study assessed and veriﬁed the
use of a novel US scoring system for CFLD. It detected previously undiagnosed
ultrasonographic liver abnormalities. These results support the need for further
evaluation of this score with liver biopsy conﬁrmation and long term follow-up.
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Background: Cystic ﬁbrosis related liver disease (CFLD) is an important cause
of mortality and morbidity in CF patients. Unfortunately sensitive diagnostic tools
to detect the early stages of CFLD are lacking, thus the diagnosis is usually only
made when advanced disease is present.
Aim: Elastography of the liver has proven to be a valuable tool to detect the early
stages of permanent liver damage in other liver diseases. This study therefore aimed
to evaluate the value of elastography in predicting early stages of CFLD.
Methods: Between January 2009 and January 2010, 100 children with CF were
prospectively included (age 4 to 18 yrs). Liver stiffness was measured by elas-
tography (Fibroscan, Echosens, Paris) with the pediatric probe, and compared to
abdominal ultrasound (US) and serum ASAT, ALAT and GGT data. Results were
compared between patients with (1) normal liver tests and US, (2) early stage
liver disease (abnormal ASAT, ALAT, GGT or mild US abnormalities, i.e. liver
irregularity) and (3) severe CFLD (incl. nodular liver edge and/or splenomegaly).
Results: Valid measurements (IQR< 30%, success rate >70%) were obtained
for 86%. In comparison to CF patients without any liver pathology, who had a
mean liver stiffness of 4.2±1.0 kPa, both patients with early stage liver disease
and patients with CFLD had a signiﬁcantly higher mean liver stiffness (6.2±4.5;
p = 0.015 and 9.2±5.3 kPa; p< 0.001, respectively).
Conclusions: Liver elastography is a useful tool for the detection of early stage
liver disease in CF patients. Elastography might also be valuable to evaluate the
effectiveness of ursodeoxycholic acid in the treatment of CFLD, which is still
uncertain.
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Background: Although the pathogenic mechanism underlying liver cirrhosis in
cystic ﬁbrosis is still unclear, a role of oxidative stress in this disease has been
suggested. Advanced oxidation protein products (AOPP) are markers of oxidant-
mediated protein damage. It has been established that the liver and the spleen play
important roles in the elimination of AOPP. Liver cirrhosis can decrease AOPP
plasma clearance that can lead to increase its plasmatic level.
Aim: To assess whether serum advanced oxidation protein products (AOPP)
concentrations are abnormal in CF patients with liver cirrhosis.
Methods: A total of 30 children with CF were included in the study. We analyzed
AOPP in the serum, comparing CF patients with liver cirrhosis (n = 12, mean age:
10.5 years, range 3.5−15) and without it (n = 18, mean age: 10.8 years, range 6−14).
Results: The plasma content of AOPP found in CF patients with liver cirrhosis
was signiﬁcantly higher compared to patients without it (56.46±7.93 and 38.3±
2.55mmol/L, mean±SEM, p = 0.022), respectively.
Conclusions: Plasma concentration of AOPP were signiﬁcantly increased in CF
children with clinical, biochemical and ultrasound evidence of liver cirrhosis.
Measurement of AOPP concentration may be useful to reveal severe liver disease
in CF patients.
